BioMedReports.Com, the news portal which covers Wall Street’s biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that Keryx Biopharmaceuticals (NASDAQ: KERX) was mentioned in a published article which contained an inaccurate statement regarding the design of a pending Phase III study for patients with metastatic colorectal cancer…

ArQule, Inc. (Nasdaq: ARQL) announced the initiation of a Phase 2, single agent trial with ARQ 197 in germ cell tumors (GCT), including testicular and non-central nervous system (non-CNS) tumors, and a Phase 1/2 clinical trial designed to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer (CRC) who possess the wild-type form of the KRAS gene. ARQ 197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase…

ArQule, Inc. (Nasdaq: ARQL) announced the initiation of a Phase 2, single agent trial with ARQ 197 in germ cell tumors (GCT), including testicular and non-central nervous system (non-CNS) tumors, and a Phase 1/2 clinical trial designed to evaluate the safety of ARQ 197 administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer (CRC) who possess the wild-type form of the KRAS gene. ARQ 197 is an orally available, small molecule inhibitor of the c-Met receptor tyrosine kinase…

Colonoscopy is operator-dependent and substantial numbers of pre-cancerous polyps are missed during colonoscopy. Colonoscopies are often poorly documented, with only a few still photographs taken of anatomic landmarks and abnormal findings. Video recording is rarely used in colonoscopy except for teaching purposes; therefore, the potential impact of systematic video recording on the quality of colonoscopy is unknown…

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Despite evidence and guidelines supporting the value of screening for this disease, rates of screening for colorectal cancer are consistently lower than those for other types of cancer, particularly breast and cervical. Although the screening rates in the target population of adults over age 50, have increased from 20-30 percent in 1997 to nearly 55 percent in 2008–the rates are still too low…

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. Despite evidence and guidelines supporting the value of screening for this disease, rates of screening for colorectal cancer are consistently lower than those for other types of cancer, particularly breast and cervical. Although the screening rates in the target population of adults over age 50, have increased from 20-30 percent in 1997 to nearly 55 percent in 2008 the rates are still too low. An NIH state-of-the-science panel was convened this week to identify ways to further increase the use and quality of colorectal cancer screening in the United States……..

Computed tomographic colonography (CTC), also known as virtual colonoscopy, remains effective in screening older patients for colorectal cancer (CRC), produces low referral for colonoscopy rates similar to other screening exams now covered by Medicare, and does not result in unreasonable levels of additional testing resulting from extracolonic findings, according to a study.

Computed tomographic colonography (CTC), also known as virtual colonoscopy, remains effective in screening older patients for colorectal cancer (CRC), produces low referral for colonoscopy rates similar to other screening exams now covered by Medicare, and does not result in unreasonable levels of additional testing resulting from extracolonic findings, according to a study published in the February issue of Radiology…

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that Erbitux® (cetuximab) provided an improvement in overall survival (OS) when added to the standard 1st-line FOLFIRI chemotherapy regimen for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors in the CRYSTAL study.1 In addition, the final results from this study included an analysis of the predictive value of BRAF status on Erbitux efficacy - one of the first to be based on a large subgroup (n=59) of a prospective, randomized study in the 1st-line setting…

IsoRay, Inc. (AMEX:ISR), announced that on October 10, 2009, Dr.